8-K: SpringWorks Therapeutics Merger with Merck KGaA Advances with Key Regulatory Approvals

SpringWorks Therapeutics, Inc. announced the satisfaction of critical antitrust conditions for its proposed merger with Merck KGaA, including the expiration of the HSR Act waiting period and Bundeskartellamt approval, moving closer to a second-half 2025 consummation.

Summary

• SpringWorks Therapeutics, Inc. (SpringWorks) entered into an Agreement and Plan of Merger (the Merger Agreement) with Merck KGaA, Darmstadt, Germany (Parent), and EMD Holdings Merger Sub, Inc. (Merger Sub) on April 27, 2025.
• Under the Merger Agreement, Merger Sub will merge with and into SpringWorks, with SpringWorks surviving as a wholly owned subsidiary of Parent.
• The Merger Agreement was approved by SpringWorks' Board of Directors.
• Completion of the Merger is subject to customary closing conditions, including the expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (HSR Act) and approval by the Bundeskartellamt (German Act Against Restraints of Competition).
• The Bundeskartellamt approved the Merger on May 20, 2025.
• The waiting period under the HSR Act expired at 11:59 p.m. Eastern Time on June 13, 2025.
• These approvals satisfy two significant conditions for the Merger's completion.
• The Merger remains subject to other closing conditions, notably the approval by a majority of outstanding shares of SpringWorks common stock at a special stockholders' meeting.
• Assuming satisfaction of all necessary closing conditions, the Merger is expected to be consummated in the second half of 2025.
• SpringWorks has filed a proxy statement on Schedule 14A with the SEC relating to a special meeting of its stockholders for the merger approval.

Sentiment

Score: 7

Explanation: The sentiment is positive as two major regulatory hurdles for the merger have been successfully cleared, indicating significant progress towards the transaction's completion. While stockholder approval is still pending, the removal of antitrust uncertainties is a strong positive signal.

Positives

• The Bundeskartellamt approved the Merger on May 20, 2025, satisfying a key regulatory condition.
• The waiting period under the HSR Act expired on June 13, 2025, fulfilling another significant antitrust condition.
• The satisfaction of these major regulatory approvals indicates significant progress towards the completion of the merger.

Risks

• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Merger Agreement.
• The satisfaction (or waiver) of closing conditions to the consummation of the proposed transaction, including the receipt of the requisite approval of SpringWorks stockholders.
• The effects of disruption from the proposed transaction contemplated by the Merger Agreement and the impact of the announcement and pendency of the proposed transaction on SpringWorks' business.
• The effects of the proposed transaction on relationships with employees, other business partners, or governmental entities.
• The response of competitors to the proposed transaction.
• Risks associated with the disruption of management's attention from ongoing business operations due to the proposed transaction.
• The ability of the parties to consummate the proposed transaction in a timely manner or at all.
• Significant costs associated with the proposed transaction.
• Potential litigation relating to the proposed transaction.
• Restrictions during the pendency of the proposed transaction that may impact SpringWorks' ability to pursue certain business opportunities.
• Risks related to the advancement of product candidates into, and successful completion of, preclinical studies and clinical trials.
• Risks and uncertainties related to regulatory application, review, and approval processes and SpringWorks' compliance with applicable legal and regulatory requirements.
• General industry conditions and competition.
• General economic factors.

Future Outlook

The Merger is expected to be consummated in the second half of 2025, assuming the satisfaction of all necessary closing conditions, including the approval of SpringWorks stockholders. The company also highlights the expected benefits and success of its product candidates, though these are subject to various risks and uncertainties.

Management Comments

• The Merger Agreement was approved by the board of directors of the Company (the Board).
• Francis I. Perier, Jr., Chief Financial Officer, signed the report on behalf of SpringWorks Therapeutics, Inc.

Industry Context

This announcement reflects a continued trend of consolidation within the biopharmaceutical industry, where larger entities like Merck KGaA acquire smaller, innovative companies like SpringWorks Therapeutics to expand their pipelines and market presence. The successful navigation of antitrust approvals is a standard, yet critical, step in such large-scale transactions.

Legal Proceedings

• Potential litigation relating to the proposed transaction is identified as a risk.

Stakeholder Impact

• Shareholders: Required to vote on the Merger Agreement, and their approval is a key closing condition. The transaction will impact their ownership.
• Employees: Potential effects of disruption from the proposed transaction and impact on relationships with employees are noted as risks.
• Business Partners: Potential effects of disruption from the proposed transaction and impact on relationships with other business partners are noted as risks.
• Governmental Entities: Impact on relationships with governmental entities is noted as a risk, though regulatory approvals have been obtained.

Next Steps

• SpringWorks stockholders need to approve the Merger Agreement by an affirmative vote of holders of at least a majority of outstanding common stock at a special meeting.
• SpringWorks may file other relevant materials with the SEC in connection with the proposed transaction.
• The Merger is expected to be consummated in the second half of 2025, assuming all remaining closing conditions are met.

Key Dates

Keywords

Merger, Acquisition, SEC Filing, 8-K, SpringWorks Therapeutics, Merck KGaA, Antitrust Approval, HSR Act, Bundeskartellamt, Regulatory Compliance, Biopharmaceutical, Corporate Transaction, Stockholder Approval